Surveys We will post links to surveys of interest to our members. Please check here often. The Common Drug Review (CDR) is currently welcoming patients to provide input to patient organizations as part of its review of upadacitinib for the treatment of psoriatic arthritis (PsA). For this submission, the Canadian Psoriasis Network is working with the Canadian Association of Psoriasis Patients, the Canadian Arthritis Patient Alliance, the Arthritis Society, and the Canadian Spondylitis Association. Your responses to this survey will only be shared among key members of our organizations as we work together to provide feedback to the Canadian Drug Review. Your responses will be kept confidential and we will not disclose any identifying information. Survey closes January 17, 2021.\u00a0Please read and scroll to bottom to start survey.